Chief Medical Officer

Apply Now!

SJP Biotec GmbH is a clinical-stage precision oncology company

pioneering a first-in-class Selective Translation Regulatory

Inhibitor (STRI) platform powered to overcome treatment

resistance in refractory cancers. Founded in 2024, SJP targets

RAS-driven, hormone-receptor-positive, and immune-refractory

tumors with a novel pipeline of small molecules developed in our

lab and ready to proceed with regulatory-grade trials.

Backed by a Scientific Advisory Board that includes world-leading

authorities in RAS and breast cancer biology, and immuno-

oncology, SJP has established clinical partnerships with leading

medical centers world-wide including UCSF, NCI, MD Anderson,

Baylor College of Medicine, MSKCC, and McGill, to name a few.

This is a stimulating and unique opportunity to join a scientifically

exceptional, capital-efficient biotech company doing

groundbreaking work at a pivotal inflection point. The CMO/SVP of

Clinical Development will serve as the company's most senior

clinical leader, responsible for designing and executing a multi-

indication clinical development strategy across one of the most

compelling areas in the current oncology drug development field -

RAS/eIF4A/translation-pathway inhibition.

Lead and oversee all clinical development activities across the SJP portfolio, including design of Phase 2/3 protocols and CTA/IND submissions to BfArM, FDA, and EMA.
Define regulatory strategy, including Fast Track, Breakthrough Therapy Designation, and accelerated approval pathways, while managing IIT partnerships and scientific interactions with clinical sites across Germany, the EU, and the US.
Develop and implement biomarker-driven patient selection strategies and present clinical data at major oncology congresses and to key opinion leaders.
Build and scale the clinical development and operations function, including recruitment of CRAs, medical monitors, and data management staff.
Support business development by preparing clinical data packages and responding to due diligence requests for licensing and out-licensing transactions.
Serve as the clinical face of the company, translating board and senior management directives, and engaging with investors and financial institutions to support capital raising activities.

MD with specialization in medical oncology and hematology, and 10+ years of hands-on clinical trial leadership experience in pharma, biotech, or CRO settings.
Demonstrated track record of successful IND/CTA submissions and direct interactions with FDA and/or EMA, including experience with accelerated approval pathways.
Deep expertise in biomarker-driven trial design, companion diagnostic development, and tumor biology across breast cancer, NSCLC, and KRAS-mutant malignancies, with a strong understanding of the competitive oncology treatment landscape.
Proven ability to manage investigator-initiated trials and academic site partnerships, complemented by a strong scientific publication and congress presentation record.
Excellent communicator and presenter with a collaborative leadership style, experienced in building and leading multidisciplinary teams of domain experts.

PhD in cancer biology with expertise in RAS/KRAS biology, MAPK pathway inhibitors, or translation-pathway therapeutics.
Experience with basket trial design and multi-cohort oncology studies, as well as background in immuno-oncology combinations, particularly in checkpoint inhibitor resistance settings.
Prior involvement in pharma partnering or licensing due diligence from the biotech side, and working knowledge of German regulatory frameworks alongside international GCP/ICH guidelines.
Established professional network at leading cancer centres.

Each employee has a chance to see the impact of his work. You can make a real contribution to the success of the company.

Zurich, Switzerland; flexibility for remote/hybrid

arrangements.

It is expected that regular travel to EU and US clinical

sites will be required.

Full-time; competitive salary; incl. Bonus.

As soon as possible.

Apply Now!